Amylyx Pharmaceuticals

AMLX · NASDAQ

$28.77+$1.44 (+5.27%)TodayMarket closed · Oct 20, 7:52 PM ET

Prev close $27.33

AMLX analyst rating

BuyConsensus of 7 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy7
Hold0
Underperform0
Sell0

12-month price target · 13 analysts

Average $43.21 (+50.2% upside)

Low: $20.20
Now: $28.77
High: $59.85

Upgrades and downgrades

The latest rating actions, newest first

AMLX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citigroup	Oct 15, 2026	Maintains	Buy	$32.00 → $39.00	60%
Guggenheim	Aug 27, 2026	Maintains	Buy	$55.00 → $57.00	57%
Mizuho	Aug 19, 2026	Maintains	Outperform	$30.00 → $42.00	54%
Guggenheim	Aug 19, 2026	Maintains	Buy	$40.00 → $55.00	57%
Baird	Aug 19, 2026	Maintains	Outperform	$28.00 → $52.00	49%
HC Wainwright & Co.	Aug 18, 2026	Maintains	Buy	$34.00 → $55.00	54%
Mizuho	Aug 17, 2026	Maintains	Outperform	$24.00 → $30.00	54%
Citigroup	Aug 3, 2026	Maintains	Buy	$20.00 → $26.00	60%
Mizuho	Jul 20, 2026	Maintains	Outperform	$21.00 → $24.00	54%
Guggenheim	Jun 25, 2026	Maintains	Buy	$30.00 → $40.00	57%

The case for and against

Updated Oct 16, 2026

Bull case

Amylyx Pharmaceuticals is positioned favorably because avexitide’s Phase 3 LUCIDITY data were highly statistically significant, with a 55% reduction in composite hypoglycemic events, all secondary endpoints met, and a clean safety profile, which materially de-risks approval in post-bariatric hypoglycemia. The company also benefits from FDA Breakthrough Therapy and Orphan Drug designations, an anticipated NDA filing by year-end, and a sizable rare-disease market with about 160,000 US patients living with PBH, supporting premium pricing, broad reimbursement, and a potentially strong launch. Beyond avexitide, the pipeline adds longer-term upside through AMX0318 and other programs, while the firm’s now improved path to profitability and modeled year-end 2027 cash balance suggest sufficient financial runway to execute on commercialization.

Bear case

Amylyx Pharmaceuticals is a clinical-stage company whose valuation depends heavily on development-stage programs, leaving it exposed to binary clinical and regulatory outcomes rather than recurring commercial revenue. The main bearish factors are the possibility that Phase 3 data in adults with PBH underperform on efficacy or safety, along with unforeseen delays in R&D, regulatory, or commercial progress that could push out or weaken future catalysts. Competitive pressure in the PBH space and the risk that the PBH market opportunity is smaller than expected further limit upside and increase the chance that the pipeline fails to justify investor expectations.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.